

REMARKS

In the current Official Action, claims 8-11 are pending of which claim 10 has been allowed.

Claim 8 is amended to exclude the compounds mentioned by the examiner in item 3, parts a) and b), of the Official Action.


Counsel submits that all of the claims in the application are now in condition for allowance. Reconsideration and favorable action are solicited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page(s) is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____




Arthur R. Crawford
Reg. No. 25,327

ARC:lsp
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

8. (Amended) A 2-aminoteraline of the formula (I)



or a pharmacologically acceptable salt of the formula (II)



wherein:

R and R₁ are independently halogen, hydroxy, or C₁-C₄ alkoxy optionally substituted in position ω with a group selected from OH, NH₂ or NR₃R₄, wherein R₃ and

R_4 are independently H, C_1 - C_4 alkyl, unsubstituted or substituted in position ω with groups OH, NH_2 , C_1 - C_4 alkanoyl, C_1 - C_4 alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted. NR_3R_4 , where R_3 and R_4 have the above meanings,

R_2 is hydrogen, halogen, hydroxy or methoxy,

with the proviso that the 2-aminotetraline excludes (a) $R=R_1=CH_3O$ or OH, $R_2=H$, (b)

$R=F$, $R_1=CH_3O$ or OH, $R_2=H$, (c) $R_1=R_2=-OCH_3$ and $R_2=H$, (d) $R=R_1=R_2=CH_3O$, (e)

$R=R_1=Cl$ and $R_2=H$, (f) $R=R_1-F$ and $R_2=H$, or (g) $R=OH$ and $R_1=R_2=halogen$, (h)

$R=R_1=OH$ and $R_2=Cl$ or F or (i) $R=R_1=OCH_3$ and $R_2=Cl$ or F,

and X^- is the monovalent anion of a pharmacologically acceptable acid.